Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 4, 2007, Pages 518-522

  Kakizaki, Satoru ^a   Sohara, Naondo ^a   Sato, Ken ^a   Suzuki, Hideyuki ^a   Yanagisawa, Masatoshi ^a   Nakajima, Hiroaki ^a   Takagi, Hitoshi ^a   Naganuma, Atsushi ^b   Otsuka, Toshiyuki ^c   Takahashi, Hitomi ^d   Hamada, Tetsuya ^e   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kiryu Kousei General Hospital   (Japan)

^c Tone Chuo Hospital   (Japan)

^d Public Tomioka General Hospital   (Japan)

^e FUJI HEAVY INDUSTRIES LTD   (Japan)

Author keywords

Chemoprevention; Hepatocellular carcinoma; Menatetrenone; Vitamin K2

Indexed keywords

MENATETRENONE; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS CARCINOGENESIS;

EID: 33947223690     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04844.x     Document Type: Article

References (17)

1. The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74: 2772-80.
2. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
3. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med. 1999; 131: 174-81.
4. Kubo S, Nishiguchi S, Hirohashi K et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann. Intern. Med. 2001; 134: 963-7.
5. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood 1999; 93: 1798-808.
6. Sakai I, Hashimoto S, Yoda M et al. Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem. Biophys. Res. Commun. 1994; 205: 1305-10.
7. Wu FYH, Liao WC, Chang HM. Comparison of antitumor activity of vitamins K1, K2, K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci. 1993; 52: 1797-804.
8. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 1995; 22: 876-82.
9. Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int. J. Hematol. 1999; 69: 24-6.
10. Liebman HA, Furie BC, Tong M et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-31.
11. Koike Y, Shiratori Y, Sato S et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. A prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
12. Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H. Changes of plasma des-γ-carboxy-prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer 1992; 69: 31-8.
13. Mizuta T, Ozaki I, Eguchi Y et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006; 106: 867-72.
14. Nishikawa Y, Carr BI, Wang M et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem. 1995; 270: 28304-10.
15. Muto Y, Moriwaki H, Ninomiya M et al. The Hepatoma Prevention Study Group. Prevention of second primary tumor by an acyclic retinoid, polyrenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med. 1996; 334: 1561-7.
16. Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J. Bone Miner. Metab. 1998; 16: 106-12.
17. Habu D, Shiomi S, Tamori A et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-61.